The use of P2X7R antagonists induced the decrease in tumour size; the upregulation of the anti-oncogenic kinase GSK-3β; and the downregulation of MYCN, HIF-1α, and VEGF [71]. This evidence concerns the gene VEGFA and neoplasm.